HomeNewsBusinessLooking at touchless tech & cloud to drive growth after COVID-19, says Hexaware CEO

Looking at touchless tech & cloud to drive growth after COVID-19, says Hexaware CEO

Hexaware suspended the guidance of 15-17 percent it gave at the beginning of the year as the back of COVID-19

April 30, 2020 / 13:40 IST
Story continues below Advertisement

Hexaware technologies will re-look its service lines to cater to the changing needs at the back of coronavirus outbreak. "This includes more focus on cloud and touchless technology," CEO R Srikrishna said.

Speaking to Moneycontrol after results announcement on April 28, Srikrishna, said that the prospect of recovery will be faster in areas such as cloud and touch-less technology. “These are not discretionary spending rather necessary for business continuity plans,” he added.

Story continues below Advertisement

For instance, even if a flight takes off with less than half the strength, they need to invest in technology for issuing boarding passes. So investment in these technologies becomes necessary, he noted.

To cater to these changing demands, the company has reoriented itself to focus on four major areas – touchless and immersive technology, cloud, automation and anywhere employee concept, where entire lifecycle of employees is made online starting from on-boarding, evaluation and employee engagement. The company is working on these services, which will be app-based.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show